Friday, November 13, 2026

Fed Signals Multiple 2026 Rate Cuts as Global Central Banks Eye Inflation Retreat

Chicago Fed President Alan Goolsbee signaled multiple US rate cuts in 2026 if inflation continues falling, aligning with dovish shifts across developed markets. The Fed expects 2-3 cuts totaling 50-75 basis points through year-end. Bond markets from New York to Frankfurt rallied on lower borrowing costs ahead.

From our archive, published before source-traceability. How we work

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
Fed Signals Multiple 2026 Rate Cuts as Global Central Banks Eye Inflation Retreat
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The Federal Reserve may cut interest rates multiple times in 2026 as inflation moderates, Chicago Fed President Alan Goolsbee said this week. "Interest rates can come down more this year if inflation does," Goolsbee stated, joining central bank chiefs from the ECB to the Bank of England in signaling easing cycles ahead.

Markets expect 2-3 US rate cuts totaling 50-75 basis points through December, contingent on core PCE inflation and employment data. The dovish pivot mirrors moves in Europe, where the ECB cut rates three times in 2025, and Japan, where the BOJ maintains ultra-low rates despite modest tightening.

For global banks, the rate-cut roadmap compresses net interest margins as loan yields fall faster than deposit costs. European lenders with southern European sovereign debt exposure face additional pressure, while Asian banks with property loan books watch China's parallel easing closely.

Bond portfolios across markets stand to benefit. US Treasuries in the 5-10 year range offer optimal positioning, while German Bunds and UK Gilts show similar dynamics. Fixed-income allocations are shifting duration-long as yields fall and prices rise globally.

Fintech growth financing improves with cheaper capital. Nordic payment firms like Finland's processors saw contactless volumes jump 23% to EUR 8.4 billion in Q2 2025, while Southeast Asian digital lenders prepare expansion amid falling rates.

The Fed pairs easing signals with tighter supervision, including climate risk assessments matching EU banking regulations. This balances loan demand growth against capital requirements—a framework echoed by regulators from Singapore to Toronto.

Timing remains data-dependent across markets. While the Fed eyes mid-2026 cuts, the ECB may move sooner if eurozone growth stalls. Synchronized easing could amplify cross-border capital flows into emerging markets seeking yield.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· February 27, 2026
    Finland Prepaid Card and Digital Wallet Market Intelligence Report 2026-2030: Edenred and ePassi Compete on App-Led Usability While Enfuce Strengthens Modular Card Issuing
  2. [2]News articleNasdaq· February 26, 2026
    Stocks Finish Mostly Lower as Nvidia Weighs on Chipmakers
  3. [3]News articleNasdaq· February 21, 2026
    Stocks Settle Higher as SCOTUS Rejects President Trump’s Tariffs
  4. [4]News articleYahoo Finance· December 12, 2025
    XRP Plans Zero-Knowledge Privacy Layer: Can Privacy Adoption Drive Price to $6?

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com